Radiopharmaceutical developer Navidea Biopharmaceuticals has initiated a sale of common stock to raise approximately $4.8 million toward its ongoing operations.
The transaction is being conducted by J.P. Morgan Asset Management and one other institutional investor and is expected to close on or near February 4, according to Navidea.
